Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MEDICINOVA INCMNOV · Entity 7011 | VP and Head of Japanese Office | February 28, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MEDICINOVA INC
Report date February 28, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,040,530 |
Ending reported balance
After 2019-02-28 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2019-02-28 · Exercise / conversion · Acquired 35,700 · Balance 189,280 Row 2 · 2019-02-28 · Exercise / conversion · Acquired 85,000 · Balance 274,280 Row 3 · 2019-02-28 · Exercise / conversion · Acquired 63,750 · Balance 338,030 Row 4 · 2019-02-28 · Exercise / conversion · Acquired 80,000 · Balance 418,030 Row 5 · 2019-02-28 · Exercise / conversion · Acquired 42,500 · Balance 460,530 Row 6 · 2019-02-28 · Exercise / conversion · Acquired 105,000 · Balance 565,530 Row 7 · 2019-02-28 · Exercise / conversion · Acquired 15,000 · Balance 580,530 Row 8 · 2019-02-28 · Exercise / conversion · Acquired 105,000 · Balance 685,530 Row 9 · 2019-02-28 · Exercise / conversion · Acquired 30,000 · Balance 715,530 Row 10 · 2019-02-28 · Exercise / conversion · Acquired 120,000 · Balance 835,530 Row 11 · 2019-02-28 · Exercise / conversion · Acquired 100,000 · Balance 935,530 Row 12 · 2019-02-28 · Exercise / conversion · Acquired 105,000 · Balance 1,040,530 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.34 · Expires 2020-01-28 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-02-28 · Exercise / conversion · Disposed 35,700 · Balance 0 F1: The option vested over a period of 4 years in equal monthly installments from the 1/28/2010 date of grant and is now fully vested. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2021-07-12 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-02-28 · Exercise / conversion · Disposed 85,000 · Balance 0 F2: The option vested over a period of 4 years in equal monthly installments from the 7/13/2011 date of grant and is now fully vested. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2021-08-02 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-02-28 · Exercise / conversion · Disposed 63,750 · Balance 0 F3: The option was granted on 8/3/2011, was subject to vesting based on achievement of performance criteria and vested in full on 6/14/2012. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2023-05-12 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2019-02-28 · Exercise / conversion · Disposed 80,000 · Balance 0 F4: The option was granted on 5/13/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/2/2013. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2023-05-12 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2019-02-28 · Exercise / conversion · Disposed 42,500 · Balance 0 F5: The option vested over a period of 4 years in equal monthly installments from the 5/13/2013 date of grant and is now fully vested. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2023-12-11 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2019-02-28 · Exercise / conversion · Disposed 105,000 · Balance 0 F6: The option was granted on 12/12/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/4/2014. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2024-12-03 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2019-02-28 · Exercise / conversion · Disposed 15,000 · Balance 0 F7: The option vested over a period of 3 years in equal monthly installments from the 12/4/2014 date of grant and is now fully vested. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09 · Expires 2025-01-06 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2019-02-28 · Exercise / conversion · Disposed 105,000 · Balance 0 F8: The option was granted on 1/7/2015, was subject to vesting based on achievement of performance criteria and vested in full on 1/7/2016. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2026-01-06 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2019-02-28 · Exercise / conversion · Disposed 30,000 · Balance 0 F9: The option vested over a period of 3 years in equal monthly installments from the 1/7/2016 date of grant and is now fully vested. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2026-01-06 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-02-28 · Exercise / conversion · Disposed 120,000 · Balance 0 F10: The option was granted on 1/7/2016, was subject to vesting based on achievement of performance criteria and vested in full on 1/18/2017. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.10 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2019-02-28 · Exercise / conversion · Disposed 100,000 · Balance 0 F11: The option was granted on 1/18/2017, was subject to vesting based on achievement of performance criteria and vested in full on 1/6/2018. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2028-01-05 | Direct | 0 |
Reported balance
After 2019-02-28 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2019-02-28 · Exercise / conversion · Disposed 105,000 · Balance 0 F12: The option was granted on 1/6/2018, was subject to vesting based on achievement of performance criteria and vested in full on 1/15/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested over a period of 4 years in equal monthly installments from the 1/28/2010 date of grant and is now fully vested.
F2: The option vested over a period of 4 years in equal monthly installments from the 7/13/2011 date of grant and is now fully vested.
F3: The option was granted on 8/3/2011, was subject to vesting based on achievement of performance criteria and vested in full on 6/14/2012.
F4: The option was granted on 5/13/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/2/2013.
F5: The option vested over a period of 4 years in equal monthly installments from the 5/13/2013 date of grant and is now fully vested.
F6: The option was granted on 12/12/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/4/2014.
F7: The option vested over a period of 3 years in equal monthly installments from the 12/4/2014 date of grant and is now fully vested.
F8: The option was granted on 1/7/2015, was subject to vesting based on achievement of performance criteria and vested in full on 1/7/2016.
F9: The option vested over a period of 3 years in equal monthly installments from the 1/7/2016 date of grant and is now fully vested.
F10: The option was granted on 1/7/2016, was subject to vesting based on achievement of performance criteria and vested in full on 1/18/2017.
F11: The option was granted on 1/18/2017, was subject to vesting based on achievement of performance criteria and vested in full on 1/6/2018.
F12: The option was granted on 1/6/2018, was subject to vesting based on achievement of performance criteria and vested in full on 1/15/2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 24 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2028-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option was granted on 1/6/2018, was subject to vesting based on achievement of performance criteria and vested in full on 1/15/2019. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 23 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option was granted on 1/18/2017, was subject to vesting based on achievement of performance criteria and vested in full on 1/6/2018. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 22 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2026-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option was granted on 1/7/2016, was subject to vesting based on achievement of performance criteria and vested in full on 1/18/2017. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 21 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vested over a period of 3 years in equal monthly installments from the 1/7/2016 date of grant and is now fully vested. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 20 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2025-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option was granted on 1/7/2015, was subject to vesting based on achievement of performance criteria and vested in full on 1/7/2016. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 19 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vested over a period of 3 years in equal monthly installments from the 12/4/2014 date of grant and is now fully vested. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 18 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2023-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on 12/12/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/4/2014. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 17 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,500 shares Expires 2023-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested over a period of 4 years in equal monthly installments from the 5/13/2013 date of grant and is now fully vested. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 16 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2023-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on 5/13/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/2/2013. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 63,750 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 15 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,750 shares Expires 2021-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on 8/3/2011, was subject to vesting based on achievement of performance criteria and vested in full on 6/14/2012. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 14 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested over a period of 4 years in equal monthly installments from the 7/13/2011 date of grant and is now fully vested. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,700 | $0.00 Strike: $7.34 | $0.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · derivative · entry 13 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested over a period of 4 years in equal monthly installments from the 1/28/2010 date of grant and is now fully vested. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 105,000 | $7.00 | $735,000.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 12 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 100,000 | $6.10 | $610,000.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 11 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 120,000 | $3.91 | $469,200.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 10 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 30,000 | $3.91 | $117,300.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 9 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 105,000 | $3.09 | $324,450.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 8 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 15,000 | $3.24 | $48,600.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 7 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 105,000 | $2.64 | $277,200.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 6 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 42,500 | $4.10 | $174,250.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 5 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 80,000 | $4.10 | $328,000.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 4 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 63,750 | $2.46 | $156,825.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 3 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 85,000 | $2.54 | $215,900.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 2 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 11:00 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 35,700 | $7.34 | $262,038.00 |
DisclosureSEC source: 0001683168-19-000530 · ownership.xml · nonDerivative · entry 1 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:24 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantEmployee Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001683168-19-000150 · ownership.xml · derivative · entry 1 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2028-01-05 F1 · balance_after: On January 06, 2018, the reporting person was granted an option to purchase 105,000 shares of common stock. The option vests based on MNOV's satisfaction of certain performance criteria for the fiscal year ended December 31, 2018. The Performance criteria for 2018 have been met, resulting in full vesting of the option. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 21:24 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,250 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001683168-19-000079 · ownership.xml · derivative · entry 2 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,250 shares Expires 2019-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested over a period of 4 years in equal monthly installments from the 1/30/2009 date of grant and is now fully vested. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 21:24 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 41,250 | $2.20 | $90,750.00 |
DisclosureSEC source: 0001683168-19-000079 · ownership.xml · nonDerivative · entry 1 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 930 shares acquired under MediciNova's employee stock purchase plan, which are exempt under Rule 16b-3(c). Read SEC document |
| January 06, 2018 Filed Jan 9, 2018 23:25 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001683168-18-000091 · okajima_f4-010618.xml · derivative · entry 1 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-17 F1 · balance_after: On January 18, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock. The option vests based on MNOV's satisfaction of certain performance criteria for the fiscal year ended December 31, 2017. The Performance criteria for 2017 have been met, resulting in full vesting of the option. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:03 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001683168-17-003308 · okajima_frm4.xml · derivative · entry 2 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires 2018-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested over a period of 4 years in equal monthly installments from the 1/7/2008 date of grant and is now fully vested. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:03 UTC | MEDICINOVA INC MNOV · Entity 7011 | Exercise / conversionCommon Stock | 48,000 | $4.42 | $212,160.00 |
DisclosureSEC source: 0001683168-17-003308 · okajima_frm4.xml · nonDerivative · entry 1 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under MediciNova's employee stock purchase plan, which are exempt under Rule 16b-3(c). Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 22:31 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001683168-17-000141 · okajima_f4.xml · derivative · entry 1 Okajima Masatsune · CIK 0001374660 · VP and Head of Japanese Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2026-01-06 F1 · balance_after: On January 7, 2016, the reporting person was granted an option to purchase 120,000 shares of common stock. The option vests based on MNOV's satisfaction of certain performance criteria by December 31, 2016. The Performance criteria have been met, resulting in full vesting of the option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.